Table 7. Summary of salvage IRE case series studies in radio-recurrent prostate cancer.

Study	Study design	Number of patients	Median follow-up duration (months)	Oncologic outcomes	Safety outcomes
Guenther et al., 2019 (62)	Multi-center, retrospective	429 (63: recurrent disease)	Max 72	Overall recurrence rate: 41 (10%) patients (5-year recurrence rate: 5.6% for Gleason 6/14.6% for Gleason 7/39.5% for Gleason 8–10)	Complications: mild (19.7%), moderate (3.7%) and severe (1.4%)
					No life-threatening complications
					Urinary continence was preserved in all cases
					IRE-induced ED persisted in 3% of the evaluated cases at post-treatment 12 months
Blazevski et al., 2023 (63)	Multi-center, prospective (FIRE trial)	37	29	27 (73%) patients: no local and systemic disease	7 (19%) patients: self-limiting urgency, frequency, or hematuria (Gr 1–2)
				4 (11%) patients: local recurrence only	7 (19%) Gr 3 complications; urethral sludge requiring transurethral resection
				6 (16%) patients: metastatic disease with a median time to metastasis of 8 months	93% of patients remained continent at post-salvage IRE 12 months
					ED deterioration: from 35% to 15% (4/27)

IRE, irreversible electroporation, ED, erectile dysfunction; Gr, grade.